Morgan Stanley raised the firm’s price target on Johnson & Johnson to $267 from $262 and keeps an Overweight rating on the shares. The firm adjusted models among its biopharma coverage for IQVIA trends as well as intra-quarter updates ahead of Q1 earnings reporting from the group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson presents clinical data for TECNIS PureSee IOL at ASCRS meeting
- Johnson & Johnson assumed with a Buy at TD Cowen
- Johnson & Johnson: Diversified Growth, Robust Pipeline, and Attractive Risk‑Reward Support Buy Rating
- Johnson & Johnson product cycle momentum continuing, says Goldman Sachs
- Johnson & Johnson announces launch of Varipulse Pro in Europe